<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5304">
  <stage>Registered</stage>
  <submitdate>7/12/2015</submitdate>
  <approvaldate>7/12/2015</approvaldate>
  <nctid>NCT02631096</nctid>
  <trial_identification>
    <studytitle>Study of ARB-001467 in Subjects With Chronic HBV Infection Receiving Nucleos(t)Ide Analogue Therapy</studytitle>
    <scientifictitle>A Phase 2a Single-Blind, Randomized, Placebo-Controlled Study Evaluating the Safety, Anti Viral Activity, and Pharmacokinetics of ARB-001467 in Non Cirrhotic, HBeAg Negative and Positive Subjects With Chronic HBV Infection Receiving Nucleos(t)Ide Analogue Therapy</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>ARB-001467-002</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Hepatitis B, Chronic</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - ARB-001467
Other interventions - Placebo

Experimental: 0.2 mg/kg ARB-001467 or Placebo - HBeAg-negative subjects randomized 3:1 to receive ARB-001467 at 0.2 mg/kg versus placebo.

Experimental: 0.4 mg/kg ARB-001467 or Placebo - HBeAg-negative subjects randomized 3:1 to receive ARB-001467 at 0.4 mg/kg versus placebo.

Experimental: ARB-001467 or Placebo - HBeAg-positive subjects randomized 3:1 to receive ARB-001467 at 0.4 mg/kg versus placebo.

Experimental: 0.4 mg/kg ARB-001467 - HBeAg-negative subjects receive ARB-001467 at. 0.4 mg/kg (open label).


Treatment: drugs: ARB-001467
An IV infusion of ARB-001467 once a month for three months.

Other interventions: Placebo
An IV infusion of placebo once a month for three months.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Frequency and severity of treatment-emergent SAEs, discontinuations due to AEs, and laboratory abnormalities, by cohort, through 28 days after the last infusion of study treatment. - To evaluate the safety and tolerability of multiple doses of ARB-001467 in HBeAg-negative and HBeAg-positive subjects with chronic Hepatitis B virus infection who are receiving nucleos(t)ide analogue therapy</outcome>
      <timepoint>Up to 4 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Evaluate ARB-001467 Maximum plasma concentration (Cmax) at multiple time points from baseline through Day 85 (i.e., 28 days after the last infusion of study treatment). - To evaluate the pharmacokinetics of multiple doses of ARB-001467 in subjects with chronic HBV infection.</outcome>
      <timepoint>Up to 12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Evaluate ARB-001467 Time to maximum plasma concentration (Tmax) at multiple time points from baseline through Day 85 (i.e., 28 days after the last infusion of study treatment). - To evaluate the pharmacokinetics of multiple doses of ARB-001467 in subjects with chronic HBV infection.</outcome>
      <timepoint>Up to 12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Evaluate ARB-001467 Area under the plasma concentration-time curve from the start of infusion to the last measurable concentration (AUC0-t) at multiple time points from baseline through Day 85 (i.e., 28 days after the last infusion of study treatment). - To evaluate the pharmacokinetics of multiple doses of ARB-001467 in subjects with chronic HBV infection.</outcome>
      <timepoint>Up to 12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Evaluate additional parameters for ARB-001467 from plasma concentration-time curve from start of infusion and extrapolated to infinity (AUC0-t), inf), partial AUCs, T1/2, volume of distribution (VD) and clearance (CL) (baseline through Day 85) - To evaluate the pharmacokinetics of multiple doses of ARB-001467 in subjects with chronic HBV infection.</outcome>
      <timepoint>Up to 12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The proportion of subjects in each dose level cohort with =0.5 log10 HBsAg decrease from baseline at end of study, and for these subjects, the changes from baseline (expressed as percentage and log10 change). - To evaluate antiviral activity of ARB-001467 for up to 72 weeks after the first dose of study treatment.</outcome>
      <timepoint>Up to 18 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Key 

          -  Documented chronic HBV infection for =12 months prior to Screening Visit.

          -  Quantitative HBsAg =1000 IU/mL at the Screening Visit.

          -  Subjects currently receiving entecavir and/or tenofovir for =12 months and HBV DNA
             undetectable.

        Key</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Known co-infection with HIV, hepatitis C virus, and hepatitis D virus.

          -  Receiving or planning to receive systemic immunosuppressive medications during the
             study or =2 months prior to the first dose of study treatment.

          -  Receiving or planning to receive interferon during the study or =12 months prior to
             the first dose of study treatment.

          -  Significant immunosuppression from, but not limited to immunodeficiency conditions
             such as common variable hypogammaglobulinemia.

          -  Clinical diagnosis of substance abuse with alcohol, narcotics, or cocaine =12 months
             prior to the Screening Visit.

          -  Any known pre-existing medical or psychiatric condition that could interfere with the
             subject's ability to provide informed consent or participate in study conduct, or that
             may confound study findings.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/12/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>36</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/04/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC,WA</recruitmentstate>
    <hospital>Monash Health, Gastroenterology and Hepatology - Clayton</hospital>
    <hospital>The Alfred, Gastroenterology and Hepatology - Melbourne</hospital>
    <hospital>Linear Clinical Research Ltd - Nedlands</hospital>
    <postcode>3168 - Clayton</postcode>
    <postcode>3004 - Melbourne</postcode>
    <postcode>6009 - Nedlands</postcode>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Hamilton</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Arbutus Biopharma Corporation</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The study is a phase 2a, single blind, randomized, placebo controlled, study evaluating the
      safety, anti-viral activity, and pharmacokinetics (PK) following multiple doses of
      intravenous ARB-001467</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02631096</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Patricia Mendez, MD, PhD</name>
      <address>Arbutus Biopharma Corporation</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Patricia Mendez, MD</name>
      <address />
      <phone>+1-908-463-4826</phone>
      <fax />
      <email>pmendez@arbutusbio.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>